Immunic Total Other Income Expense Net from 2010 to 2025

IMUX Stock  USD 1.18  0.01  0.85%   
Immunic Total Other Income Expense Net yearly trend continues to be fairly stable with very little volatility. Total Other Income Expense Net is likely to outpace its year average in 2025. During the period from 2010 to 2025, Immunic Total Other Income Expense Net regression line of annual values had significance of  0.35 and arithmetic mean of  2,880,768. View All Fundamentals
 
Total Other Income Expense Net  
First Reported
2012-09-30
Previous Quarter
1.4 M
Current Value
1.4 M
Quarterly Volatility
1.8 M
 
Yuan Drop
 
Covid
Check Immunic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunic's main balance sheet or income statement drivers, such as Depreciation And Amortization of 94.9 K, Interest Expense of 730.2 K or Other Operating Expenses of 119.8 M, as well as many indicators such as Price To Sales Ratio of 17.3 K, Dividend Yield of 0.0064 or PTB Ratio of 1.46. Immunic financial statements analysis is a perfect complement when working with Immunic Valuation or Volatility modules.
  
Check out the analysis of Immunic Correlation against competitors.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

Latest Immunic's Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of Immunic over the last few years. It is Immunic's Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunic's overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Pretty Stable
   Total Other Income Expense Net   
       Timeline  

Immunic Total Other Income Expense Net Regression Statistics

Arithmetic Mean2,880,768
Coefficient Of Variation155.75
Mean Deviation3,492,239
Median2,675,000
Standard Deviation4,486,877
Sample Variance20.1T
Range15.5M
R-Value(0.25)
Mean Square Error20.2T
R-Squared0.06
Significance0.35
Slope(237,828)
Total Sum of Squares302T

Immunic Total Other Income Expense Net History

20255.3 M
2024M
20235.6 M
2022-919 K
2021-1.3 M
2020M
20192.1 M

About Immunic Financial Statements

Immunic investors use historical fundamental indicators, such as Immunic's Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunic. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Other Income Expense NetM5.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunic Stock Analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.